MedTrace Logo

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

NCT04385589 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-02-16

No results posted yet for this study

Summary

We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients with acute decompensated heart failure owing to its diuretic effect in addition to improvement of blood glucose level without remarkable effect on kidney function or electrolytes.

Conditions

Interventions

DRUG

Dapagliflozin

Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.

DRUG

insulin

insulin

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ayman Ibrahem, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-12-15
Completion
2020-12-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385589 on ClinicalTrials.gov